Drugs and other chemical substances inducing diabetes – review of the literature
DOI:
https://doi.org/10.56782/pps.183Keywords:
type 3 diabetes, secondary diabetes, drug-induced diabetes, drug-induced hyperglycemia, insulin resistanceAbstract
A Type 3 diabetes, classified as secondary diabetes, includes drug-induced or chemical-induced forms of diabetes. We distinguish many types of drugs that can induce diabetes, among others commonly used glucocorticosteroids, β-blockers and diuretics, antidepressants and antipsychotics, statins, or antiviral drugs.
We aimed to evaluate the impact of chosen drugs and other chemical substances on glycemic control, to analyse the mechanisms of development of drug-induced diabetes and to propose the therapeutic procedures. We conducted the literature review using the Pubmed and Google Scholar. We analysed reviews, systematic reviews, meta-analysis, randomized controlled trials, clinical trials, and observational studies published from 2013 to 2024.
Mechanisms of diabetes development are various and complex. However, we need to underline the role of drug-induced weight gain. The duration of therapy is also important because longer therapy is usually associated with higher risk of development of diabetes.
Drug-induced diabetes is a significant clinical problem. The benefits of using the drug often outweigh the side effects associated with poor glycemic control. Currently, pharmacotherapy of drug-induced diabetes is similar to the standards of treatment for other types of diabetes. Changing therapy to the drug with lower metabolic risk should be considered as far as possible. Moreover, due to common presence of pesticides, heavy metals and endocrine-disrupting chemicals, inducing diabetes is also very problematic and constitutes an important area of new scientific researches.
Downloads
References
Petersmann, A.; Nauck, M.; Müller-Wieland, D.; Kerner, W.; Müller, U.A.; Landgraf, R. i in. Definition, Classification and Diagnosis of Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes 2018,126(7),406–410. doi:10.1055/a-0584-6223 DOI: https://doi.org/10.1055/a-0584-6223
Angelopoulos T.P.; Tentolouris N.K.; Bertsias G.K.; Boumpas D.T. Steroid-induced diabetes in rheumatologic patients. Clin. Exp. Rheumatol. 2014, 32(1),126–30.
Fathallah, N.; Slim, R.; Larif, S.; Hmouda, H.; Ben Salem, C. Drug-Induced Hyperglycaemia and Diabetes. Drug. Saf. 2015,38(12),1153–68. doi:10.1007/s40264-015-0339-z DOI: https://doi.org/10.1007/s40264-015-0339-z
Okruszko, M.A.; Szabłowski, M.; Pochodowicz, K.; Taranta-Janusz, K.; Bossowski, A.; Głowińska-Olszewska, B. Atypical diabetes mellitus in children – when to suspect drug-induced diabetes. A case-based review of the literature. Pediatr. Endocrinol. Diabetes. Me. 2022, 28(4), 294–300. doi:10.5114/pedm.2022.118398 DOI: https://doi.org/10.5114/pedm.2022.118398
Jain, V.; Patel, R.K.; Kapadia, Z.; Galiveeti, S.; Banerji, M.; Hope, L. Drugs and hyperglycemia: A practical guide. Maturitas 2017, 104, 80–83. doi:10.1016/j.maturitas.2017.08.006 DOI: https://doi.org/10.1016/j.maturitas.2017.08.006
Fève, B.; Scheen, A.J. When therapeutic drugs lead to diabetes. Diabetologia 2022, 65(5), 751–762. doi:10.1007/s00125-022-05666-w DOI: https://doi.org/10.1007/s00125-022-05666-w
Hirst, J.A.; Farmer, A.J.; Feakins, B.G.; Aronson, J.K.; Stevens, R.J.; Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2015, 79(5), 733–43. doi:10.1111/bcp.12543 DOI: https://doi.org/10.1111/bcp.12543
Bhattacharjee, S.; Bhattacharya, R.; Kelley, G.A.; Sambamoorthi, U. Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes/metabolism research and reviews 2013, 29(4), 273-284. doi:10.1002/dmrr.2393 DOI: https://doi.org/10.1002/dmrr.2393
Elena, C.; Chiara, M.; Angelica, B.; Chiara, M.A.; Laura, N.; Chiara, C.; i in. Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations. Curr. Pharm. Biotechnol. 2018, 19(15), 1210–1220. doi:10.2174/1389201020666190102145305 DOI: https://doi.org/10.2174/1389201020666190102145305
Hwang, J.L.; Weiss, R.E. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes. Metab. Res. Rev. 2014, 30(2), 96–102. doi:10.1002/dmrr.2486 DOI: https://doi.org/10.1002/dmrr.2486
Patel, D.A.; Kristensen, P.L.; Pedersen-Bjergaard, U.; Schultz, H.H. Glucocorticoid-induced diabetes and risk factors during high-dose therapy. Ugeskr. Laeger. 2018, 180(18), V06170454.
Descours, M.; Rigalleau, V. Glucocorticoid-induced hyperglycemia and diabetes: Practical points. Ann. Endocrinol. (Paris) 2023, 84(3), 353–6. doi:10.1016/j.ando.2023.03.011 DOI: https://doi.org/10.1016/j.ando.2023.03.011
Aberer, F.; Hochfellner, D.A.; Sourij, H.; Mader, J.K. A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. J. Clin. Med. 2021, 10(10), Art. No: 2154. doi:10.3390/jcm10102154 DOI: https://doi.org/10.3390/jcm10102154
Dąbrowski, P.; Majdan, M. Diagnosis and therapy of steroid-induced hyperglycemia based on literature reports. Wiad. Lek. 2016, 69(4), 642–5.
Phan, K.; Smith, S.D. Topical corticosteroids and risk of diabetes mellitus: systematic review and meta-analysis. J. Dermatolog. Treat. 2021, 32(3), 345–9. doi:10.1080/09546634.2019.1657224 DOI: https://doi.org/10.1080/09546634.2019.1657224
Miravitlles, M.; Auladell-Rispau, A.; Monteagudo, M.; Vázquez-Niebla J.C.; Mohammed, J.; Nuñez, A. i in. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur. Respir. Rev. 2021, 30(160), Art. No: 210075. doi:10.1183/16000617.0075-2021 DOI: https://doi.org/10.1183/16000617.0075-2021
Listyoko A.S.; Okazaki R.; Harada T.; Inui G.; Yamasaki A. Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes. Front. Med. (Lausanne). 2024, 11, Art. No: 1305638. doi: 10.3389/fmed.2024.1305638. PMID: 38343638; PMCID: PMC10853455. DOI: https://doi.org/10.3389/fmed.2024.1305638
Pu, X.; Liu, L.; Feng, B.; Zhang, Z.; Wang, G. Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis. Respir. Res. 2021, 22(1), 201. doi:10.1186/s12931-021-01789-7 DOI: https://doi.org/10.1186/s12931-021-01789-7
Vidler, J.; Rogers, C.; Yallop, D.; Devereux, S.; Wellving, E.; Stewart, O. i in. Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. J. Clin. Transl. Endocrinol. 2017, 9, 18–20. doi:10.1016/j.jcte.2017.06.003 DOI: https://doi.org/10.1016/j.jcte.2017.06.003
Drucis, M.; Irga-Jaworska, N.; Myśliwiec, M. Steroid-induced diabetes in the paediatric population. Pediatr. Endocrinol. Diabetes Metab. 2018, 24(3), 136–9. doi:10.5114/pedm.2018.80995 DOI: https://doi.org/10.5114/pedm.2018.80995
De Micheli, A. Corticosteroid induced diabetes mellitus: diagnosis and management. G. Ital. Nefrol. Malattie Metaboliche e Rene 2016, 33(S68), gin/33.S68.7.
Bell, D.S.H.; Goncalves, E. Diabetogenic effects of cardioprotective drugs. Diabetes. Obes. Metab. 2021, 23(4), 877–85. doi:10.1111/dom.14295 DOI: https://doi.org/10.1111/dom.14295
Fularska, K.; Oleszko, M.; Wąsiewicz, E.; Kuźniar, A.; Szawica, D. Beta-blockers used in cardiac failure and blood glucose level impairment - a literature review. J. Educ. Health Sport. 2023, 23(1), 40–51. DOI: https://doi.org/10.12775/JEHS.2023.23.01.005
Zullo, A.R.; Hersey. M.; Lee, Y.; Sharmin, S.; Bosco, E.; Daiello, L.A. i in. Outcomes of „diabetes-friendly” vs „diabetes-unfriendly” β-blockers in older nursing home residents with diabetes after acute myocardial infarction. Diabetes. Obes. Metab. 2018, 20(12), 2724–32. DOI: https://doi.org/10.1111/dom.13451
Mancia, G. Preventing new-onset diabetes in thiazide-treated patients. Lancet Diabetes Endocrinol. 2016, 4(2), 90–2. DOI: https://doi.org/10.1016/S2213-8587(15)00391-5
Roth, J.; Müller, N.; Kuniss, N.; Wolf, G.; Müller, U.A. Association Between Glycaemic Control and the Intake of Thiazide Diuretics, Beta Blockers and Levothyroxine in People Without Diabetes. Exp. Clin. Endocrinol. Diabetes 2021, 129(6), 443–8. doi:10.1055/a-0919-4525 DOI: https://doi.org/10.1055/a-0919-4525
Shen, L.; Shah, B.R.; Reyes, E.M.; Thomas, L.; Wojdyla, D, Diem P, i in. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013, 347, Art. No: f6745. doi:10.1136/bmj.f6745 DOI: https://doi.org/10.1136/bmj.f6745
Deuschle, M. Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr. Opin. Psychiatry 2013, 26(1), 60–5. doi:10.1097/YCO.0b013e32835a4206 DOI: https://doi.org/10.1097/YCO.0b013e32835a4206
Wang, Y.; Liu, D.; Li, X.; Liu, Y.; Wu, Y. Antidepressants use and the risk of type 2 diabetes mellitus: A systematic review and meta-analysis. J. Affect. Disord. 2021, 287, 41–53. doi:10.1016/j.jad.2021.03.023 DOI: https://doi.org/10.1016/j.jad.2021.03.023
Austin-Zimmerman, I.; Wronska, M.; Wang, B.; Irizar, H.; Thygesen, J.H.; Bhat, A.; i in. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. Genes (Basel). 2021, 12(11), Art. No: 1758. DOI: https://doi.org/10.3390/genes12111758
Owen, R.R.; Drummond, KL.; Viverito, K.M.; Marchant, K.; Pope, S.K.; Smith, J.L. i in. Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation. Implement. Sci. 2013, 8, Art. No: 120. doi:10.1186/1748-5908-8-120 DOI: https://doi.org/10.1186/1748-5908-8-120
Pérez-Iglesias, R.; Martínez-García, O.; Pardo-Garcia, G.; Amado, J.A.; Garcia-Unzueta, MT.; Tabares-Seisdedos, R. i in. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int. J. Neuropsychopharmacol. 2014, 17(1), 41–51. doi:10.1017/S1461145713001053 DOI: https://doi.org/10.1017/S1461145713001053
Grajales, D.; Ferreira, V.; Valverde, Á.M. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. Cells. 2019, 8(11), Art. No: 1336. doi:10.3390/cells8111336 DOI: https://doi.org/10.3390/cells8111336
Kowalchuk, C.; Teo, C.; Wilson, V.; Chintoh, A.; Lam, L.; Agarwal, S.M. i in. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. J. Psychiatry. Neurosci. 2017, 42(6), 424–31. doi:10.1503/jpn.170092 DOI: https://doi.org/10.1503/jpn.170092
Crespo-Facorro, B.; Prieto, C.; Sainz, J. Schizophrenia gene expression profile reverted to normal levels by antipsychotics. Int. J. Neuropsychopharmacol. 2014, 18(4), Art. No: pyu066. doi:10.1093/ijnp/pyu066 DOI: https://doi.org/10.1093/ijnp/pyu066
Siskind, D.J.; Russell, A.W.; Gamble, C.; Winckel, K.; Mayfield, K.; Hollingworth, S. i in. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes. Obes. Metab. 2018, 20(4),1050–5. doi:10.1111/dom.13167 DOI: https://doi.org/10.1111/dom.13167
Larsen, J.R.; Vedtofte, L.; Holst, J.J.; Oturai, P.; Kjær, A.; Corell, C.U. i in. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open 2014, 4(3), Art. No: e004227. doi:10.1136/bmjopen-2013-004227 DOI: https://doi.org/10.1136/bmjopen-2013-004227
Casula, M.; Mozzanica, F.; Scotti, L.; Tragni, E.; Pirillo, A.; Corrao, G. i in. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr. Metab. Cardiovasc. Dis. 2017, 27(5), 396–406. doi:10.1016/j.numecd.2017.03.001 DOI: https://doi.org/10.1016/j.numecd.2017.03.001
Galicia-Garcia, U.; Jebari, S.; Larrea-Sebal, A.; Uribe K.B.; Siddiqi, H.; Ostolaza, H. i in. Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int. J. Mol. Sci. 2020, 21(13), Art. No: 4725. doi:10.3390/ijms21134725 DOI: https://doi.org/10.3390/ijms21134725
Swerdlow, D.I.; Preiss, D. Genetic insights into statin-associated diabetes risk. Curr. Opin. Lipidol. 2016, 27(2), 125–30. doi:10.1097/MOL.0000000000000272 DOI: https://doi.org/10.1097/MOL.0000000000000272
Climent, E.; Benaiges, D.; Pedro-Botet, J. Statin treatment and increased diabetes risk. Possible mechanisms. Clin. Investig. Arterioscler. 2019, 31(5), 228–32. doi:10.1016/j.arteri.2018.12.001 DOI: https://doi.org/10.1016/j.arteri.2018.12.001
McCann, K.; Shah, S.; Hindley, L.; Hill, A.; Qavi, A.; Simmons, B. i in. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS 2021, 35(10), 1657–65. doi:10.1097/QAD.0000000000002930 DOI: https://doi.org/10.1097/QAD.0000000000002930
Nansseu, J.R.; Bigna, J.J.; Kaze, A.D.; Noubiap, J.J. Incidence and Risk Factors for Prediabetes and Diabetes Mellitus Among HIV-infected Adults on Antiretroviral Therapy: A Systematic Review and Meta-analysis. Epidemiology 2018, 29(3), 431–41. doi:10.1097/EDE.0000000000000815 DOI: https://doi.org/10.1097/EDE.0000000000000815
Nduka, C.U.; Stranges, S.; Kimani, P.K.; Sarki, A.M.; Uthman, O.A. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab. Res. Rev. 2017, 33(6), Art. No: e2902. doi:10.1002/dmrr.2902 DOI: https://doi.org/10.1002/dmrr.2902
Mesfin Belay, D.; Alebachew Bayih, W.; Yeshambel Alemu, A.; Kefale Mekonen, D.; Eshetie Aynew, Y.; Senbeta Jimma, M. i in. Diabetes mellitus among adults on highly active anti-retroviral therapy and its associated factors in Ethiopia: Systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2021, 182, 109125. doi:10.1016/j.diabres.2021.109125 DOI: https://doi.org/10.1016/j.diabres.2021.109125
Echecopar-Sabogal, J.; D’Angelo-Piaggio, L.; Chanamé-Baca, D.M.; Ugarte-Gil, C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. Int. J. STD. AIDS. 2018, 29(5), 443–52. doi:10.1177/0956462417732226 DOI: https://doi.org/10.1177/0956462417732226
Spinner, C.D.; Schulz, S.; Bauer, U.; Schneider, J.; Bobardt, J.; Werder, A.V. i in. Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: The TAF-IR Study. Antiviral Therapy. 2018, 23(7), 629–32. DOI: https://doi.org/10.3851/IMP3271
Tadesse, W.T.; Adankie, B.T.; Shibeshi, W.; Amogne, W.; Aklillu, E.; Engidawork, E. Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy. PLoS One 2022, 17(1), Art. No: e0262604. doi:10.1371/journal.pone.0262604 DOI: https://doi.org/10.1371/journal.pone.0262604
Parise, R.; Deruiter, J.; Ren, J.; Govindarajulu, M.; Ramesh, S.; Nadar, RM. i in. Impact of COVID-19 therapy on hyperglycemia. Diab. Vasc. Dis. Res. 2022, 19(3), Art. No: 14791641221095091. doi:10.1177/14791641221095091 DOI: https://doi.org/10.1177/14791641221095091
Xia, J.; Yu, J.; Xu, H.; Zhou, Y.; Li, H.; Yin, S. i in. Comparative effects of vitamin and mineral supplements in the management of type 2 diabetes in primary care: A systematic review and network meta-analysis of randomized controlled trials. Pharmacol. Res. 2023, 188, Art. No: 106647. doi:10.1016/j.phrs.2023.106647 DOI: https://doi.org/10.1016/j.phrs.2023.106647
Kamanna, VS.; Ganji, S.H.; Kashyap, M.L. Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol. 2013, 24(3), 239–45. doi:10.1097/MOL.0b013e3283613a68 DOI: https://doi.org/10.1097/MOL.0b013e3283613a68
Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, DP. Nicotinic Acid and new-onset diabetes. Horm. Metab. Res. 2015, 47(7), 544–5. doi:10.1055/s-0034-1387703 DOI: https://doi.org/10.1055/s-0034-1387703
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart. J. 2013, 34(17), 1279–91. doi:10.1093/eurheartj/eht055 DOI: https://doi.org/10.1093/eurheartj/eht055
Goldie, C.; Taylor, A.J.; Nguyen, P.; McCoy, C.; Zhao, X.Q.; Preiss, D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart 2016, 102(3), 198–203. doi:10.1136/heartjnl-2015-308055 DOI: https://doi.org/10.1136/heartjnl-2015-308055
Li, D.; Luo, N.; Ma, Q.; Li, SZ.; Shi, Q.; Cao, Y. i in. Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats. Pharm. Biol. 2013, 51(1), 8–12. doi:10.3109/13880209.2012.697175 DOI: https://doi.org/10.3109/13880209.2012.697175
Anděl, M.; Němcová, V.; Pavlíková, N.; Urbanová, J.; Cecháková, M.; Havlová, A. i in. [Factors causing damage and destruction of beta-cells of the islets of Langerhans in the pancreas]. Vnitr. Lek. 2014, 60(9), 684–90.
Sverkeli, L.J.; Hayat, F.; Migaud, M.E.; Ziegler, M. Enzymatic and Chemical Syntheses of Vacor Analogs of Nicotinamide Riboside, NMN and NAD. Biomolecules 2021, 11(7), Art. No: 1044. doi:10.3390/biom11071044 DOI: https://doi.org/10.3390/biom11071044
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013, 37(Supplement_1), 81–90. doi:10.2337/dc14-S081 DOI: https://doi.org/10.2337/dc14-S081
Hafiz, S.; Kyriakopoulos, C. Pentamidine. W: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cytowane 12 listopada 2023]. Dostępne na: http://www.ncbi.nlm.nih.gov/books/NBK557586/
Román-Álamo, L.; Allaw, M.; Avalos-Padilla, Y.; Manca M.L.; Manconi, M.; Fulgheri, F. i in. In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis. Pharmaceutics 2023, 15(4), Art. No: 1163. doi:10.3390/pharmaceutics15041163 DOI: https://doi.org/10.3390/pharmaceutics15041163
Gadelha, E.P.N.; Ramasawmy, R.; Oliveira, B da C.; Rocha, N.M.; Guerra, JA de O.; Silva, GAVR da. i in. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. PLOS Neglected Tropical Diseases 2018, 12(10), Art. No: e0006850. doi:10.1371/journal.pntd.0006850 DOI: https://doi.org/10.1371/journal.pntd.0006850
Srinivas, N.R.; Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives. Eur. J. Drug. Metab. Pharmacokinet. 2015, 40(1), 1–12. doi:10.1007/s13318-014-0186-9 DOI: https://doi.org/10.1007/s13318-014-0186-9
Araujo, J.; Paradis, A.; Mendes, J.; Petrik, S.; de Rivera, C. Induction of Type I Diabetes Mellitus in Beagle Dogs Using Alloxan and Streptozotocin. Curr. Protoc. 2022, 2(11), Art. No: e580. doi:10.1002/cpz1.580 DOI: https://doi.org/10.1002/cpz1.580
Pérez-Bermejo, M.; Mas-Pérez, I.; Murillo-Llorente, M.T. The Role of the Bisphenol A in Diabetes and Obesity. Biomedicines. 2021, 9(6), 666.
doi:10.3390/biomedicines9060666 DOI: https://doi.org/10.3390/biomedicines9060666
Farrugia, F.; Aquilina, A.; Vassallo, J.; Pace, N.P. Bisphenol A and Type 2 Diabetes Mellitus: A Review of Epidemiologic, Functional, and Early Life Factors. Int. J. Environ. Res. Public. Health. 2021,18(2), 716. doi:10.3390/ijerph18020716 DOI: https://doi.org/10.3390/ijerph18020716
Tudurí, E.; Marroqui, L.; Dos Santos, R.S.; Quesada, I.; Fuentes, E.; Alonso-Magdalena, P. Timing of Exposure and Bisphenol-A: Implications for Diabetes Development. Front. Endocrinol. (Lausanne). 2018, 9, Art. No: 648. doi:10.3389/fendo.2018.00648 DOI: https://doi.org/10.3389/fendo.2018.00648
Provvisiero, D.P.; Pivonello, C.; Muscogiuri, G.; Negri, M.; de Angelis, C.; Simeoli, C.; i in. Influence of Bisphenol A on Type 2 Diabetes Mellitus. Int. J. Environ. Res. Public. Health. 2016, 13(10), Art. No: 989. doi:10.3390/ijerph13100989 DOI: https://doi.org/10.3390/ijerph13100989
Martínez-Pinna, J.; Sempere-Navarro, R.; Medina-Gali, R.M.; Fuentes, E.; Quesada, I.; Sargis, R.M.; i in. Endocrine disruptors in plastics alter β-cell physiology and increase the risk of diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 2023, 324(6), E488–505. doi:10.1152/ajpendo.00068.2023 DOI: https://doi.org/10.1152/ajpendo.00068.2023
Hwang, S.; Lim, J.E.; Choi, Y.; Jee, S.H. Bisphenol A exposure and type 2 diabetes mellitus risk: a meta-analysis. BMC Endocr. Disord. 2018,18(1), Art. No: 81. doi:10.1186/s12902-018-0310-y DOI: https://doi.org/10.1186/s12902-018-0310-y
Khalil, W.J.; Akeblersane, M.; Khan, A.S.; Moin, A.S.M.; Butler, A.E. Environmental Pollution and the Risk of Developing Metabolic Disorders: Obesity and Diabetes. Int. J. Mol. Sci. 2023, 24(10), Art. No: 8870. doi:10.3390/ijms24108870 DOI: https://doi.org/10.3390/ijms24108870
Ma, C.; Wei, D.; Wang, L.; Xu, Q.; Wang, J.; Shi, J. i in. Co-exposure of organophosphorus pesticides is associated with increased risk of type 2 diabetes mellitus in a Chinese population. Chemosphere. 2023, 332, 138865. doi:10.1016/j.chemosphere.2023.138865 DOI: https://doi.org/10.1016/j.chemosphere.2023.138865
Chung, Y.L.; Hou, Y.C.; Wang, I.K.; Lu, K.C.; Yen, T.H. Organophosphate pesticides and new-onset diabetes mellitus: From molecular mechanisms to a possible therapeutic perspective. World. J. Diabetes. 2021, 12(11), 1818–31. doi:10.4239/wjd.v12.i11.1818 DOI: https://doi.org/10.4239/wjd.v12.i11.1818
Zhao, L.; Liu, Q.; Jia, Y.; Lin, H.; Yu, Y.; Chen, X. i in. The Associations between Organophosphate Pesticides (OPs) and Respiratory Disease, Diabetes Mellitus, and Cardiovascular Disease: A Review and Meta-Analysis of Observational Studies. Toxics 2023, 11(9), Art. No: 741. doi:10.3390/toxics11090741 DOI: https://doi.org/10.3390/toxics11090741
Liu, S.H.; Lin, J.L.; Shen, H.L.; Chang, C.C.; Huang, W.H.; Weng, C.H. i in. Acute large-dose exposure to organophosphates in patients with and without diabetes mellitus: analysis of mortality rate and new-onset diabetes mellitus. Environ. Health. 2014, 13, Art. No: 11. doi:10.1186/1476-069X-13-11 DOI: https://doi.org/10.1186/1476-069X-13-11
Evangelou, E.; Ntritsos, G.; Chondrogiorgi, M.; Kavvoura, F.K.; Hernández, A.F.; Ntzani, E.E. i in. Exposure to pesticides and diabetes: A systematic review and meta-analysis. Environment International. 2016, 91, 60–8. doi:10.1016/j.envint.2016.02.013 DOI: https://doi.org/10.1016/j.envint.2016.02.013
Xiao, X.; Clark, J.M.; Park, Y. Potential contribution of insecticide exposure and development of obesity and type 2 diabetes. Food. Chem. Toxicol. 2017, 105, 456–74. doi:10.1016/j.fct.2017.05.003 DOI: https://doi.org/10.1016/j.fct.2017.05.003
Yusuf Habibullah, K.O.; Ito, R.; Stari, L.; Kishida, K.; Ohtsubo, Y.; Masai, E. i in. Degradation of DDT by γ-hexachlorocyclohexane dehydrochlorinase LinA. Biosci. Biotechnol. Biochem. 2023, 88(1), 123–30.
doi:10.1093/bbb/zbad141 DOI: https://doi.org/10.1093/bbb/zbad141
Yipei, Y.; Zhilin, L.; Yuhong, L.; Meng, W.; Huijun, W.; Chang, S. i in. Assessing the risk of diabetes in participants with DDT DDE exposure- A systematic review and meta-analysis. Environ. Res. 2022, 210, Art. No: 113018. doi:10.1016/j.envres.2022.113018 DOI: https://doi.org/10.1016/j.envres.2022.113018
Elmore, S.E.; La Merrill, M.A. Oxidative Phosphorylation Impairment by DDT and DDE. Front. Endocrinol. (Lausanne). 2019, 10, Art. No: 122.
doi:10.3389/fendo.2019.00122 DOI: https://doi.org/10.3389/fendo.2019.00122
Pavlikova, N.; Smetana, P.; Halada, P.; Kovar, J. Effect of prolonged exposure to sublethal concentrations of DDT and DDE on protein expression in human pancreatic beta cells. Environ. Res. 2015, 142, 257–63. doi:10.1016/j.envres.2015.06.046 DOI: https://doi.org/10.1016/j.envres.2015.06.046
Cetkovic-Cvrlje, M.; Olson, M.; Schindler, B.; Gong, H.K. Exposure to DDT metabolite p,p’-DDE increases autoimmune type 1 diabetes incidence in NOD mouse model. J. Immunotoxicol. 2016, 13(1), 108–18.
doi:10.3109/1547691X.2015.1017060 DOI: https://doi.org/10.3109/1547691X.2015.1017060
Javaid, A.; Akbar, I.; Javed, H.; Khan, U.; Iftikhar, H.; Zahra, D.; i in. Role of Heavy Metals in Diabetes: Mechanisms and Treatment Strategies. Crit. Rev. Eukaryot. Gene. Expr. 2021, 31(3), 65–80.
doi:10.1615/CritRevEukaryotGeneExpr.2021037971 DOI: https://doi.org/10.1615/CritRevEukaryotGeneExpr.2021037971
Sha, W.; Hu, F.; Xi, Y.; Chu, Y.; Bu, S. Mechanism of Ferroptosis and Its Role in Type 2 Diabetes Mellitus. J. Diabetes. Res. 2021, 2021, Art. No: 9999612.
doi:10.1155/2021/9999612 DOI: https://doi.org/10.1155/2021/9999612
Bjørklund G, Dadar M, Pivina L, Doşa MD, Semenova Y, Aaseth J. The Role of Zinc and Copper in Insulin Resistance and Diabetes Mellitus. Curr. Med. Chem. 2020, 27(39), 6643–57. doi:10.2174/0929867326666190902122155 DOI: https://doi.org/10.2174/0929867326666190902122155
Cai, J.; Li, Y.; Liu, S.; Liu, Q.; Min, Xu.; Zhang, J.; i in. Associations between multiple heavy metals exposure and glycated hemoglobin in a Chinese population. Chemosphere 2022, 287(Pt 2), Art. No: 132159. doi:10.1016/j.chemosphere.2021.132159 DOI: https://doi.org/10.1016/j.chemosphere.2021.132159
Chang, W.; Li, P. Copper and Diabetes: Current Research and Prospect. Mol. Nutr. Food. Res. 2023, 67(23), Art.No: e2300468. doi:10.1002/mnfr.202300468 DOI: https://doi.org/10.1002/mnfr.202300468
Zhang, F.; Li, X.; Wei, Y. Selenium and Selenoproteins in Health. Biomolecules. 2023, 13(5), Art. No: 799. doi:10.3390/biom13050799 DOI: https://doi.org/10.3390/biom13050799
Steinbrenner, H.; Duntas, L.H.; Rayman, M.P. The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities. Redox. Biol. 2022, 50, Art. No: 102236. doi:10.1016/j.redox.2022.102236 DOI: https://doi.org/10.1016/j.redox.2022.102236
Hong, H.; Xu, Y.; Xu, J.; Zhang, J.; Xi, Y.; Pi, H. i in. Cadmium exposure impairs pancreatic β-cell function and exaggerates diabetes by disrupting lipid metabolism. Environ. Int. 2021, 149, Art. No: 106406. doi:10.1016/j.envint.2021.106406 DOI: https://doi.org/10.1016/j.envint.2021.106406
Filippini, T.; Wise, L.A.; Vinceti, M. Cadmium exposure and risk of diabetes and prediabetes: A systematic review and dose-response meta-analysis. Environ. Int. 2022, 158, Art. No: 106920. doi:10.1016/j.envint.2021.106920 DOI: https://doi.org/10.1016/j.envint.2021.106920
Hendryx, M.; Luo, J.; Chojenta, C.; Byles, J.E. Exposure to heavy metals from point pollution sources and risk of incident type 2 diabetes among women: a prospective cohort analysis. Int. J. Environ. Health Res. 2021, 31(4), 453–64. doi:10.1080/09603123.2019.1668545 DOI: https://doi.org/10.1080/09603123.2019.1668545
Tuculina, M.J.; Perlea, P.; Gheorghiță, M.; Cumpătă C.N.; Dascălu, I.T.; Turcu, A.; i in. Diabetes mellitus: Plasticizers and nanomaterials acting as endocrine-disrupting chemicals (Review). Exp. Ther. Med. 2022, 23(4), Art. No: 288. doi:10.3892/etm.2022.11217 DOI: https://doi.org/10.3892/etm.2022.11217
Eales, J.; Bethel, A.; Galloway, T.; Hopkinson, P.; Morrissey, K.; Short, R.E. i in. Human health impacts of exposure to phthalate plasticizers: An overview of reviews. Environ. Int. 2022, 158, 106903.
doi:10.1016/j.envint.2021.106903 DOI: https://doi.org/10.1016/j.envint.2021.106903
Zhang, H.; Ben, Y.; Han, Y.; Zhang, Y.; Li, Y.; Chen, X. Phthalate exposure and risk of diabetes mellitus: Implications from a systematic review and meta-analysis. Environ. Res. 2022, 204, Art. No: 112109. doi:10.1016/j.envres.2021.112109 DOI: https://doi.org/10.1016/j.envres.2021.112109
Mariana, M.; Cairrao, E. The Relationship between Phthalates and Diabetes: A Review. Metabolites. 2023, 13(6), Art. No: 746. doi:10.3390/metabo13060746 DOI: https://doi.org/10.3390/metabo13060746
Renzelli, V.; Gallo, M.; Morviducci, L.; Marino, G.; Ragni, A.; Tuveri, E. i in. Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer. Cancers (Basel). 2023, 15(17), 4237. doi:10.3390/cancers15174237 DOI: https://doi.org/10.3390/cancers15174237
Barton, B.B.; Segger, F.; Fischer, K.; Obermeier, M.; Musil, R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020, 19(3), 295–314. doi: 10.1080/14740338.2020.1713091 DOI: https://doi.org/10.1080/14740338.2020.1713091
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
